Difference between revisions of "Trastuzumab and hyaluronidase (Herceptin Hylecta)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
|||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2/28/2019: Initial approval for the treatment of [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|overexpressing]] [[breast cancer]]. | + | *2/28/2019: Initial approval for the treatment of [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|overexpressing]] [[breast cancer]]. ''(Based on HannaH)'' |
==Also known as== | ==Also known as== | ||
Revision as of 00:15, 12 June 2022
Mechanism of action
From the NCI Drug Dictionary: A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream.
Diseases for which it is used
History of changes in FDA indication
- 2/28/2019: Initial approval for the treatment of HER2-overexpressing breast cancer. (Based on HannaH)
Also known as
- Generic name: trastuzumab and hyaluronidase-oysk
- Brand name: Herceptin Hylecta